EUVIMEDEUVIMED entdecken
Multizentrische Studie

Serum biomarkers at disease onset for personalized therapy in multiple sclerosis

Enric Monreal iD, José Ignacio Fernández-Velasco iD, Roberto Álvarez-Lafuente iD, Susana Sainz de la Maza, María Isabel García-Sánchez, Sara Llufriu, Bonaventura Casanova, Manuel Comabella iD, Sergio Martínez-Yélamos, Daniela Galimberti, Lluís Ramió-Torrentà, María Luisa Martínez-Ginés und 27 weitere

Brain · 03.12.2024 · 147 (12) · 4084-4093

DOI: 10.1093/brain/awae260 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Brain, online erschienen am 05.08.2024. Verfasst von Enric Monreal und 38 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Hospital Universitario Ramón y Cajal, Red Española de Esclerosis Múltiple (REEM), Red de Enfermedades Inflamatorias (REI), I…. Hauptthemen laut MEDLINE: Biomarkers, Neurofilament Proteins, Multiple Sclerosis, Precision Medicine. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Red Española de Esclerosis Múltiple, Red Española de Enfermedades Inflamatorias, REI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The potential for combining serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels to predict worsening disability in multiple sclerosis remains underexplored. We aimed to investigate whether sNfL and sGFAP values identify distinct subgroups of patients according to the risk of disability worsening and their response to disease-modifying treatments (DMTs). This multicentre study, conducted across 13 European hospitals, spanned from 15 July 1994 to 18 August 2022, with follow-up until 26 September 2023. We enrolled patients with multiple sclerosis who had serum samples collected within 12 months from disease onset and before initiating DMTs. Multivariable regression models were used to estimate the risk of relapse-associated worsening (RAW), progression independent of relapse activity (PIRA) and Expanded Disability Status Scale (EDSS) score of 3. Of the 725 patients included, the median age was 34.2 (interquartile range, 27.6–42.4) years, and 509 patients (70.2%) were female. The median follow-up duration was 6.43 (interquartile range, 4.65–9.81) years. Higher sNfL values were associated with an elevated risk of RAW [hazard ratio (HR) of 1.45; 95% confidence interval (CI) 1.19–1.76; P < 0.001], PIRA (HR of 1.43; 95% CI 1.13–1.81; P = 0.003) and reaching an EDSS of 3 (HR of 1.55; 95% CI 1.29–1.85; P < 0.001). Moreover, higher sGFAP levels were linked to a higher risk of achieving an EDSS score of 3 (HR of 1.36; 95% CI 1.06–1.74; P = 0.02) and, in patients with low sNfL values, to PIRA (HR of 1.86; 95% CI 1.01–3.45; P = 0.04). We also examined the combined effect of sNfL and sGFAP levels. Patients with low sNfL and sGFAP values exhibited a low risk of all outcomes and served as a reference. Untreated patients with high sNfL levels showed a higher risk of RAW, PIRA and reaching an EDSS of 3. Injectable or oral DMTs reduced the risk of RAW in these patients but failed to mitigate the risk of PIRA and reaching an EDSS of 3. Conversely, high-efficacy DMTs counteracted the heightened risk of these outcomes, except for the risk of PIRA in patients with high sNfL and sGFAP levels. Patients with low sNfL and high sGFAP values showed an increased risk of PIRA and achieving an EDSS of 3, which remained unchanged with either high-efficacy or other DMTs. In conclusion, evaluating sNfL and sGFAP levels at disease onset in multiple sclerosis might identify distinct phenotypes associated with diverse immunological pathways of disability acquisition and therapeutic response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersNeurofilament ProteinsMultiple SclerosisPrecision MedicineHumansFemaleMaleAdultGlial Fibrillary Acidic ProteinDisease ProgressionFollow-Up StudiesMiddle Aged

Stichwörter der Autor:innen

clinically isolated syndromeglial fibrillary acidic proteinmultiple sclerosisneurofilament light chainprogression

Substanzen

Biomarkersneurofilament protein LNeurofilament ProteinsGlial Fibrillary Acidic ProteinGFAP protein, human

Autor:innen und Institutionen

  • Department of Neurology, Hospital Universitario Ramón y Cajal, Red Española de Esclerosis Múltiple (REEM), Red de Enfermedades Inflamatorias (REI), IRYCIS, Universidad de Alcalá, 28034 Madrid, Spain.
  • Department of Immunology, Hospital Universitario Ramón y Cajal, REEM, REI, IRYCIS, Universidad de Alcalá, 28034 Madrid, Spain.
  • Grupo Investigación de factores ambientales en enfermedades degenerativas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain.
  • Nodo Biobanco Hospital Virgen Macarena (Biobanco del Sistema Sanitario Público de Andalucía), Hospital Universitario Virgen Macarena, 41013 Seville, Spain.
  • Neuroimmunology and Multiple Sclerosis Unit, Laboratory of Advanced Imaging in Neuroimmunological Diseases, Hospital Clinic Barcelona, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS) and Universitat d…
  • Multiple Sclerosis and Neuroimmunology Research Group, Fundación para la Investigación La Fe, 46026 Valencia, Spain.

ORCID-Profile: Enric Monreal, José Ignacio Fernández-Velasco, Roberto Álvarez-Lafuente, Manuel Comabella, Ana Quiroga-Varela, Luisa M Villar

Förderung

  • Red Española de Esclerosis Múltiple
  • Red Española de Enfermedades Inflamatorias
  • REI
  • Plan Estatal I + D + I
  • ISCIII-Subdirección General de Evaluación
  • Fondo Europeo de Desarrollo Regional
  • Otra manera de hacer Europa
  • Biobank Nodo Hospital Virgen Macarena

Zitieren

APA

Monreal, E., Fernández-Velasco, J. I., Álvarez-Lafuente, R., Sainz de la Maza, S., García-Sánchez, M. I., Llufriu, S., Casanova, B., Comabella, M., Martínez-Yélamos, S., Galimberti, D., Ramió-Torrentà, L., Martínez-Ginés, M. L., Aladro, Y., Ayuso, L., Martínez-Rodríguez, J. E., Brieva, L., Villarrubia, N., Eichau, S., Zamora, J., …, & Villar, L. M. (2024). Serum biomarkers at disease onset for personalized therapy in multiple sclerosis. Brain, 147(12), 4084-4093. https://doi.org/10.1093/brain/awae260

Vancouver

Monreal E, Fernández-Velasco JI, Álvarez-Lafuente R, Sainz de la Maza S, García-Sánchez MI, Llufriu S, et al. Serum biomarkers at disease onset for personalized therapy in multiple sclerosis. Brain. 2024;147(12):4084-4093. doi:10.1093/brain/awae260

BibTeX
@article{Monreal2024,
  author = {Monreal, Enric and Fernández-Velasco, José Ignacio and Álvarez-Lafuente, Roberto and Sainz de la Maza, Susana and García-Sánchez, María Isabel and Llufriu, Sara and Casanova, Bonaventura and Comabella, Manuel and Martínez-Yélamos, Sergio and Galimberti, Daniela and Ramió-Torrentà, Lluís and Martínez-Ginés, María Luisa and Aladro, Yolanda and Ayuso, Lucía and Martínez-Rodríguez, José Enrique and Brieva, Luis and Villarrubia, Noelia and Eichau, Sara and Zamora, Javier and Rodero-Romero, Alexander and Espiño, Mercedes and Blanco, Yolanda and Saiz, Albert and Montalbán, Xavier and Tintoré, Mar and Domínguez-Mozo, María Inmaculada and Cuello, Juan Pablo and Romero-Pinel, Lucía and Ghezzi, Laura and Pilo de la Fuente, Belén and Pérez-Miralles, Francisco and Quiroga-Varela, Ana and Rubio, Lluïsa and Rodríguez-Jorge, Fernando and Chico-García, Juan Luís and Sainz-Amo, Raquel and Masjuan, Jaime and Costa-Frossard, Lucienne and Villar, Luisa M},
  title = {Serum biomarkers at disease onset for personalized therapy in multiple sclerosis},
  journal = {Brain},
  year = {2024},
  volume = {147},
  number = {12},
  pages = {4084--4093},
  doi = {10.1093/brain/awae260}
}
Kostenlos starten →